Approval · Notice of Compliance 28231 · 2022
NIMENRIX: Notice of Compliance 28231
Issued May 18, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28231
- Date
- May 18, 2022
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate drug substance manufacturing facility
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NIMENRIX | Not yet assigned | — |
Medicinal ingredients
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C 5 MCG per 0.5ML
- MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y 5 MCG per 0.5ML
- TETANUS TOXOID 44 MCG per 0.5ML